Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

Abstract Background Patients with metastatic renal cell cancer (mRCC) are commonly treated with the tyrosine kinase inhibitor sunitinib, which blocks signalling from vascular endothelial growth factor (VEGF) - and platelet-derived growth factor-receptors, inhibiting development of new blood vessels....

Full description

Bibliographic Details
Main Authors: Marjut Niinivirta, Maria Georganaki, Gunilla Enblad, Cecilia Lindskog, Anna Dimberg, Gustav J. Ullenhag
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Cancer
Subjects:
ELTD1
Predictive marker
Renal cancer
Tissue microarray
Tyrosine kinase inhibitor
Online Access:http://link.springer.com/article/10.1186/s12885-020-06770-z

Internet

http://link.springer.com/article/10.1186/s12885-020-06770-z

Similar Items